An unexpected result of obesity treatment: Orlistat-related acute pancreatitis

Creative Commons License

Köse M., Emet S., Akpınar T. S., İlhan M., Gök A. F. K., Dadashov M., ...Daha Fazla

Case Reports in Gastroenterology, cilt.9, ss.152-155, 2015 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1159/000430433
  • Dergi Adı: Case Reports in Gastroenterology
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.152-155
  • İstanbul Üniversitesi Adresli: Evet

Özet

Orlistat is a pancreatic lipase inhibitor which is used to treat obesity. Due to the increasing prevalence of obesity, orlistat use is thought to rise progressively. We report an interesting case caused by orlistat use caught in the early stages of acute pancreatitis through imaging; in addition, the case had significantly elevated serum amylase levels. A 54-year-old male who had a history of orlistat treatment started 7 days before was admitted to the emergency department with complaints of abdominal pain, nausea and vomiting lasting for 24 h. Abdominal computed tomography revealed peripancreatic fat tissue edema and a heterogeneous appearance of the pancreas. Based on these findings, it was concluded that edematous pancreatitis was in its initial stage. Orlistat is a drug that is increasingly widespread use due to obesity. More attention must be paid when planning to prescribe orlistat to patients if there are risk factors for acute pancreatitis (alcohol use, height, serum calcium and lipid levels)